Dr. Christopher Gardner

A geeky science thing, because I know you're a data science guy. It's fun. The primary outcome for that study was the cytokine response score. So in the world of inflammation, nobody has a single thing that they all like, not C-reactive protein, not interleukin-6, not trimethylamine oxide.

A geeky science thing, because I know you're a data science guy. It's fun. The primary outcome for that study was the cytokine response score. So in the world of inflammation, nobody has a single thing that they all like, not C-reactive protein, not interleukin-6, not trimethylamine oxide.

There's all kinds of things floating out there, but there isn't one that clinicians agree on and measure in the clinic. So Mark Davis had found this sort of cluster of 14 different things in a paper that they found looking within that population. They said, maybe people should be looking at the cytokine response score and then on

There's all kinds of things floating out there, but there isn't one that clinicians agree on and measure in the clinic. So Mark Davis had found this sort of cluster of 14 different things in a paper that they found looking within that population. They said, maybe people should be looking at the cytokine response score and then on

There's all kinds of things floating out there, but there isn't one that clinicians agree on and measure in the clinic. So Mark Davis had found this sort of cluster of 14 different things in a paper that they found looking within that population. They said, maybe people should be looking at the cytokine response score and then on

clinicaltrials.gov, we said that's our primary outcome and we're going to look at all this other stuff. And in the cell paper, cytokine response score didn't change. And since then, Mark Davis has kind of abandoned this score because it hasn't been reproduced in other populations. But I think it's really interesting from a paper publishing point of view that the reviewers caught it.

clinicaltrials.gov, we said that's our primary outcome and we're going to look at all this other stuff. And in the cell paper, cytokine response score didn't change. And since then, Mark Davis has kind of abandoned this score because it hasn't been reproduced in other populations. But I think it's really interesting from a paper publishing point of view that the reviewers caught it.

clinicaltrials.gov, we said that's our primary outcome and we're going to look at all this other stuff. And in the cell paper, cytokine response score didn't change. And since then, Mark Davis has kind of abandoned this score because it hasn't been reproduced in other populations. But I think it's really interesting from a paper publishing point of view that the reviewers caught it.

They said, look, in this paper, your primary outcome didn't change. All it changes is you're seeing are secondary and exploratory. But we kind of admit that you have 90 markers and 20 get better and nothing gets worse. That's probably worth talking about. So this is how nuanced that is. And the Fiverr story is nuanced. It wasn't 100 people. It was 18 people. And we divide them into groups of six.

They said, look, in this paper, your primary outcome didn't change. All it changes is you're seeing are secondary and exploratory. But we kind of admit that you have 90 markers and 20 get better and nothing gets worse. That's probably worth talking about. So this is how nuanced that is. And the Fiverr story is nuanced. It wasn't 100 people. It was 18 people. And we divide them into groups of six.

They said, look, in this paper, your primary outcome didn't change. All it changes is you're seeing are secondary and exploratory. But we kind of admit that you have 90 markers and 20 get better and nothing gets worse. That's probably worth talking about. So this is how nuanced that is. And the Fiverr story is nuanced. It wasn't 100 people. It was 18 people. And we divide them into groups of six.

Very exploratory. And yet, that paper has now been cited a thousand times.

Very exploratory. And yet, that paper has now been cited a thousand times.

Very exploratory. And yet, that paper has now been cited a thousand times.

Got to look out for that. So an interesting part of this study is, again, because it's a six-week maintenance phase of this thing, we had to make a big difference. So if there's a signal you don't want to miss a small signal. So in some of our studies, we kind of exaggerate. We go vegan, even though we're not expecting the world to go vegan. We just want them to eat more plants.

Got to look out for that. So an interesting part of this study is, again, because it's a six-week maintenance phase of this thing, we had to make a big difference. So if there's a signal you don't want to miss a small signal. So in some of our studies, we kind of exaggerate. We go vegan, even though we're not expecting the world to go vegan. We just want them to eat more plants.

Got to look out for that. So an interesting part of this study is, again, because it's a six-week maintenance phase of this thing, we had to make a big difference. So if there's a signal you don't want to miss a small signal. So in some of our studies, we kind of exaggerate. We go vegan, even though we're not expecting the world to go vegan. We just want them to eat more plants.

We went to six servings because they were eating a half a serving before. And to just say, why don't you double that to one? It's like, okay, we're not going to get a perturbation of metabolism with one. Let's go to six. The interesting thing was, Four weeks after the study ended, this group of 18 that were eating basically no fermented food at first were still eating three servings a day.

We went to six servings because they were eating a half a serving before. And to just say, why don't you double that to one? It's like, okay, we're not going to get a perturbation of metabolism with one. Let's go to six. The interesting thing was, Four weeks after the study ended, this group of 18 that were eating basically no fermented food at first were still eating three servings a day.

We went to six servings because they were eating a half a serving before. And to just say, why don't you double that to one? It's like, okay, we're not going to get a perturbation of metabolism with one. Let's go to six. The interesting thing was, Four weeks after the study ended, this group of 18 that were eating basically no fermented food at first were still eating three servings a day.